For decades, dental health innovation has been the hidden chapter in healthcare. Startups with groundbreaking solutions have struggled to secure funding, while oral health continues to be overlooked in the investment world.

That’s why Revere Partners x GHIN&F came together to change the narrative. They envisioned a space where dental innovation gets the spotlight it deserves — and so Wisdom Innovation Partners was born.

This isn’t just another fund. It’s a response to an urgent need:
1. To elevate dental innovation as a crucial part of healthcare.
2. To support startups like Proteocyte and Decon7 that are already transforming patient care.
3. To connect investors and visionaries in a market expected to grow to $731B by 2032.

GHIF II is now live and actively fundraising to ensure continued support to Raydiant.

Global Health Impact Fund (GHIF) is a clinician-founded healthcare venture capital firm based in Silicon Valley, with a proven track record of identifying and supporting transformative healthtech startups.

Our inaugural fund, GHIF I — launched in 2019 and fully subscribed at $10M — has achieved two successful exits from 10 investments:

• Somnoware, acquired by ResMed in 2023 (3.3x return)

• UBERDOC, acquired by ROV Investment Partners in 2025

We’re now raising GHIF II, targeting $50M, with a first close at $25M. Notably, 40% of GHIF I Limited Partners have already reinvested — a strong vote of confidence in our strategy and performance.

A key focus of GHIF II is Raydiant Oximetry, a clinical-stage medical device company advancing maternal and fetal health. GHIF has been a committed investor since Raydiant’s seed round in 2019, supporting its FDA approval, major grants from the Gates Foundation and NIH, and a recent joint development initiative with GE HealthCare.

GHIF II plans to participate in Raydiant’s Series B round, with an anticipated exit in 2026 offering strong return potential.

GHIF II is now live and actively fundraising to ensure continued support to Raydiant.

This roundtable brought together key leaders in women’s health innovation. The session brought together key voices advancing innovation in women's health across capital, clinical, and technology ecosystems — including representatives from GHIF, CBIV, and UCSF.

• Sheetal Nariani, General Partner & CFO, GHIF

• Dr. Janet Moore Goldman, Maternal-Fetal Medicine Specialist, UCSF

• Annie Thériault & Megan Dover, Managing Partners, Cross-Border Impact Ventures

Key Takeaways:

• Massive innovation gap: For decades, pregnant women were excluded from clinical trials. This is only now being addressed with inclusive design, research, and technology.

• High investor interest: Despite historical underfunding, femtech is showing strong deal flow, with key focus areas like maternal health, menopause, and fertility access.

• Strong M&A appetite: Strategic acquirers are actively seeking innovations in maternal and women's health, from diagnostics to AI-based tools.

• Next-gen solutions: From predictive ultrasound tech to at-home monitoring and inclusive cancer diagnostics, startups are solving urgent and overlooked problems.

• Platform plays matter: Investors are prioritizing scalable, multi-product solutions with the potential for significant impact and venture-level returns.

GHIF II will continue investing in bold innovations that transform women’s health — with a focus on underserved markets, inclusive product development, and measurable patient outcomes.